Chemistry:Evobrutinib

From HandWiki

Evobrutinib is an experimental drug being studied for the treatment of encephalomyelitis and multiple sclerosis.[1][2][3] It is an inhibitor of Bruton's tyrosine kinase.[4]

References

  1. ↑ "Evobrutinib". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800041955. 
  2. ↑ "Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study". Multiple Sclerosis 30 (4–5): 558–570. April 2024. doi:10.1177/13524585241234783. PMID 38436271. 
  3. ↑ "Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials". The Lancet. Neurology 23 (11): 1119–1132. November 2024. doi:10.1016/S1474-4422(24)00328-4. PMID 39307151. 
  4. ↑ "Evobrutinib". Multiple Sclerosis Trust. https://mstrust.org.uk/a-z/evobrutinib. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Evobrutinib&oldid=4031540"